🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

CVS Health Corporation CVS SPXR3KPHARMA

Healthcare · Healthcare Plans · United States
https://www.cvshealth.com
Company Profile ↓
$96.74
+51.46% 1Y
Mkt Cap$123.73B
P/E25.53
P/B1.53
Div. Yield2.76%
52W High$109.92
52W Low$63.87
Book Value$62.37
EPS (TTM)$3.79

Company Overview

CVS Health Corporation provides health solutions in the United States. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services, including medical, pharmacy, dental, and behavioral health plans; medical management capabilities; Medicare Advantage and Medicare Supplement plans; prescription drug plans (PDPs); and Medicaid health care management services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Health Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, specialty and mail-order pharmacy, clinical services, disease management, medical spend management services, and pharmacy and other administrative services. It serves employers, insurance companies, unions, government employee groups, health plans, PDPs, Medicaid managed care plans, CMS, plans offered on public health insurance exchanges, and other sponsors of health benefit plans. The Pharmacy & Consumer Wellness segment sells prescription and over-the-counter drugs, consumer health and beauty products, personal care products, and other general merchandise products. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. It operates online retail pharmacy websites, retail specialty pharmacy stores, and compounding pharmacies, as well as branches for infusion and enteral nutrition services. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1963 and is headquartered in Woonsocket, Rhode Island.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 10.3% CAGR over the past five years.

Dividend Income

Offers a dividend yield of 2.76%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $402.07B (+7.8% YoY); net profit $1.77B.
  • Trailing 12 Months Year-on-year growth — revenue +7.1%, earnings +188.8%.
  • 5-Year Trend Long-term compounding — revenue CAGR 10.3%, profit CAGR -2.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:10.27%
1 Year:7.10%

Compounded Profit Growth

5 Years:-2.32%
1 Year:188.80%

Stock Price Performance

1 Year:+51.46%
6 Months:+26.02%
3 Months:+1.47%
1 Month:+0.54%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 71% of range
$63.87 $109.92
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • RSI (14)49.74 · Neutral
Price Performance
1M+0.54%
3M+1.47%
6M+26.02%
1Y+51.46%
Valuation vs Sector

P/E of 25.53 is above the sector median of 25.17 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 10.3% over 5 years.
  • Attractive dividend yield of 2.76%.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Earnings shrank at -2.3% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
25.53
Industry PE
25.17
Forward P/E
11.43
PEG Ratio
0.27
Book Value
$62.37
Price to Book
1.53
P/S
0.30
EV/EBITDA
11.09
Dividend Yield
2.76%

Growth (CAGR)

Revenue 5Y
10.27%
Profit 5Y
-2.32%
Revenue (YoY)
7.10%
Earnings (YoY)
188.80%

Profitability & Returns

ROCE
6.30%
ROE
6.21%
ROA
2.97%
Profit Margin
1.18%
Op Margin
3.86%
Gross Margin
13.65%
EPS (Latest Qtr)
$2.31
EPS (TTM)
$3.79

Balance Sheet & Liquidity

Debt/Equity
0.96
Quick Ratio
0.62
Current Ratio
0.87
Debt
$76.31B
Total Assets
$253.77B
Current Assets
$74.82B
Working Capital
$-11.59B

Ownership

Promoter Holding
0.06%
Chg in Prom Hold
0.00%
FII / Inst Holding
90.77%
Chg in FII Hold
-0.09%

Financial Snapshot

Enterprise Value
$123.73B
Total Revenue (TTM)
$412.64B
EBITDA
$16.68B
Free Cash Flow
$8.08B
Operating Cash Flow
$14.78B
Shares Outstanding
1.28B
Gross Margin
13.65%
Payout Ratio
70.18%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 CVS CVS Health Corporation SPXR3KPHARMA 96.74 25.53 $123.73B 2.76% 6.30% 6.21% 10.27% -2.32%
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,149.36 38.57 $1.02T 0.58% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 275.23 31.97 $663.28B 2.09% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 256.46 72.45 $453.19B 2.84% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 150.33 120.26 $371.29B 2.65% - 34.70% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 397.14 25.54 $356.47B 2.33% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 159.99 24.20 $304.10B 3.03% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 162.70 24.36 $252.33B 1.98% 15.97% 21.96% 9.82% 45.96%
9 AMGN Amgen Inc. NDXSPXR3KPHARMA 437.23 27.14 $235.98B 2.49% 13.95% 91.47% 5.51% 5.55%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026Jun 2026
Revenue ------------45.69B46.71B47.27B-61.40B63.14B64.55B---------------------
Gross Profit 6.16B6.40B6.66B7.30B6.74B7.01B7.49B7.61B6.57B6.93B7.12B7.90B6.86B7.20B7.33B-------------------------
Operating Income 2.13B2.26B2.33B2.73B2.19B2.36B2.82B3.00B1.80B2.12B2.50B3.11B2.00B-1.37B2.57B824.00M2.69B3.33B2.93B3.04B3.46B4.68B3.25B3.58B4.33B3.06B3.54B4.67B-3.92B3.45B3.23B3.69B2.27B3.04B832.00M3.37B2.38B-3.21B4.68B4.70B
Net Income 1.22B1.27B1.25B1.50B1.15B924.00M1.54B1.71B952.00M1.10B1.28B3.29B998.00M-2.56B1.39B-419.00M1.42B1.94B1.53B1.75B2.01B2.98B1.22B2.22B2.78B1.60B2.35B3.03B-3.41B2.14B1.90B2.26B1.11B1.77B87.00M1.78B1.02B-3.98B2.94B2.98B
Diluted EPS 1.071.121.111.341.040.861.431.590.921.071.263.220.98-2.521.36-0.371.091.491.171.331.532.260.931.682.101.201.772.29-2.591.651.481.750.881.410.071.410.80-3.132.302.31

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 76.33B87.47B98.22B95.78B107.08B123.12B126.76B139.37B153.29B177.53B184.76B193.92B256.78B268.71B-322.47B357.78B372.81B402.07B
Cost of Revenue ---------------267.96B303.35B321.41B346.70B
Gross Profit 16.11B18.29B20.36B20.22B20.56B22.49B23.78B25.37B26.53B28.86B28.55B----54.50B54.43B51.40B55.36B
Operating Expenses ---------------38.21B39.83B41.71B44.98B
Operating Income 4.79B6.05B6.42B6.14B6.33B7.21B8.04B8.80B9.47B10.39B9.54B4.02B11.99B13.91B-16.29B14.60B9.70B10.38B
EBITDA ---------------12.35B18.20B13.70B9.86B
Interest Expense ---------------2.29B2.66B2.96B3.12B
Pretax Income ---------------5.84B11.17B6.15B2.14B
Tax Provision ---------------1.51B2.81B1.56B408.00M
Net Income 2.64B3.20B3.70B3.43B3.46B3.86B4.59B4.64B5.24B5.32B6.62B-594.00M6.63B7.18B-4.31B8.34B4.61B1.77B
Diluted EPS 1.922.182.552.492.573.023.743.964.634.906.44-0.575.085.46-3.266.473.661.39

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Jan 2019Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --60.96B61.64B62.17B64.85B66.22B71.53B74.19B92.44B94.46B95.13B196.46B216.67B222.45B230.72B233.00B228.28B249.73B253.22B253.54B
Total Equity -31.32B34.57B35.77B37.70B38.01B37.65B37.94B37.96B37.20B36.83B37.69B58.23B58.40B63.86B69.39B75.08B71.47B76.46B75.56B75.21B
Cash & Equivalents 530.00M1.06B1.35B1.09B1.43B1.41B1.38B4.09B2.48B2.46B3.37B1.70B4.06B-5.68B7.85B9.41B12.95B8.20B8.59B8.45B
Long Term Debt --8.06B8.76B8.65B9.21B9.13B12.84B11.63B26.27B25.61B22.18B71.44B71.35B-------
Total Liabilities -----------57.44B137.91B157.95B158.28B161.01B157.62B156.51B173.09B177.49B178.16B
Current Liabilities --13.49B12.30B11.07B11.96B14.15B15.43B19.03B23.17B26.25B30.65B44.01B45.76B53.30B62.02B67.81B69.42B79.19B84.61B88.69B

Cash Flows (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 3.23B3.95B4.04B4.78B5.86B6.67B5.78B8.14B8.54B10.14B8.01B8.87B12.85B15.87B-16.18B13.43B9.11B10.64B
Investing Cash Flow -3.08B-4.58B-1.07B-1.64B-2.41B-1.85B-1.83B-4.04B-13.42B-2.47B-2.88B-43.28B-3.34B-5.53B--5.05B-20.89B-7.61B-5.87B
Financing Cash Flow 378.00M929.00M-3.23B-2.80B-3.46B-4.86B-1.24B-5.69B4.88B-6.76B-6.75B36.82B-7.65B-7.70B--10.52B2.68B-1.14B-4.94B
Capital Expenditure -1.80B-2.18B-2.55B-2.00B-1.87B-2.03B-1.98B-2.14B-2.37B-2.22B-1.92B-2.04B-2.46B-2.44B--2.73B-3.03B-2.78B-2.83B
Free Cash Flow 1.43B1.77B1.49B2.77B3.98B4.64B3.80B6.00B6.17B7.92B6.09B6.83B10.39B13.43B-13.45B10.39B6.33B7.81B
Net Change in Cash ---------------614.00M-4.78B359.00M-172.00M
Share Buybacks 5.37B23.00M2.48B1.50B3.00B4.33B3.98B4.00B5.00B4.46B4.36B00003.50B2.01B3.02B0
Dividends Paid 323.00M383.00M439.00M479.00M674.00M829.00M1.10B1.29B1.58B1.84B2.05B2.04B2.60B2.62B2.62B2.91B3.13B3.37B3.40B

Ratios (Annual)

Figures in %.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 21.1%20.9%20.7%21.1%19.2%18.3%18.8%18.2%17.3%16.3%15.4%----16.9%15.2%13.8%13.8%
Operating Margin % 6.3%6.9%6.5%6.4%5.9%5.9%6.3%6.3%6.2%5.9%5.2%2.1%4.7%5.2%-5.1%4.1%2.6%2.6%
Net Margin % 3.5%3.7%3.8%3.6%3.2%3.1%3.6%3.3%3.4%3.0%3.6%-0.3%2.6%2.7%-1.3%2.3%1.2%0.4%
ROE % 8.4%9.2%10.3%9.1%9.1%10.3%12.1%12.2%14.1%14.4%17.6%-1.0%10.4%10.3%-6.0%10.9%6.1%2.4%
ROCE % -12.7%13.0%12.0%12.0%13.8%14.3%16.0%13.7%15.2%14.8%2.6%7.1%8.2%-10.3%8.6%5.8%6.3%

Shareholding Pattern

Insiders
0.06%
Institutions
90.77%
Public Float
90.83%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 9.63% 123.22M $11.47B
2 Vanguard Capital Management LLC 6.51% 83.32M $7.75B
3 Capital World Investors 5.86% 74.95M $6.98B
4 State Street Corporation 4.71% 60.28M $5.61B
5 Dodge & Cox Inc. 3.91% 50.01M $4.65B
6 Wellington Management Group, LLP 2.64% 33.80M $3.15B
7 Geode Capital Management, LLC 2.34% 29.90M $2.78B
8 FMR, LLC 2.26% 28.92M $2.69B
9 Vanguard Portfolio Management LLC 2.08% 26.64M $2.48B
10 Capital Research Global Investors 1.90% 24.33M $2.26B

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for CVS

Google News Sun, 06 Sep 2026

CVS Health (CVS) Stock Looks Below Fair Value But Mixed After 65% Return - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxPMzhEZkphR3RLR2ktb0Z1UnhKR3FCSVdsSllKN09RZkxKdl8zaTZtQWxrd0Y4M1lTcUItYjBPQWRrYy1GbkdmRkFUbWFYRmFJNk1lXzFRSF9haXVVS0Y1M1d3MnRNcjRaSm4tbVdOSmFWdDBWNFpiX1NjZXBCZlIzMktKTzh6Z01wRUJvaX…

Google News hu, 03 Sep 2026

CVS Stock Has Left Its Peers Behind. Or Has It? - Trefis

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxPM3JCX29QZE4zWVZ4MmVJSzctWDFZN3BRVDFHaHJRS09qWlRMVEs0d0YwbXpac0hGMEYtQUl5MENzd3pTckNtbEZwX2k4QjV0Njd0YjdvMDBXQm5aUmxoQTkyMVNQU3IwM3VWdmlxVkpIaFFLcG5oSlJYa2psUG5sSmtROWZVbFlyak5wdU…

Google News Mon, 07 Sep 2026

Here's How CVS Is Focusing on Aetna's Profitability Turnaround - TradingView

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxOSU5BZzRBMlpjMDdrbnFXejFSSTVvRmk5Q1pPazg3eHliT3hHck9aYlo0eWhHQlptaUFhNkw5cW80Rm1ldTV4Ni1BVmZvSDlZdDRUczBMbmJTcnUzdGlBVzFPcDF5dlR6UUVXMGlCM1JTQmEtaG84NXRGeFVUY1E3TkFwMmxPYWZnY19HZj…

Google News Mon, 07 Sep 2026

CVS Health Corporation $CVS Shares Purchased by Amundi - marketbeat.com

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxNcEZZMjdXQ2w3RGFwZE1fZzk5aFNicEl4cGExMFdWaWY4SkZFb2dDOEp3RERxU3c0NGNUaUFPUGtadTMtcGNVQl8yVkY5NEppSmVlZkI2UHp0TkxMVThuN2Nrc3VNaWIwVEFyR0ptejRXQXplVS16bG16ZG03bFJqamtQcG9CbWZNOGlySD…

Google News Mon, 07 Sep 2026

CVS Health Corp stock holds steady as investors digest strong earnings and outlook - ad-hoc-news.de

<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxPaWl6R0p3b2prN01MRFppekdncm5Wb1BjTGFqUWZFMENQMXJLNXJiQ1hJYU41Q0oyTzJHS0xjT1FDQW5HRmM5amppVjRaUktyMllUM054YU1BMnpLYzJRd1U0ejFXQllCYjdpY2J6czNNOFpkVUszZ1p4MGJSaFhJWGpWY2l6SDExZ2hxNn…

Google News ue, 01 Sep 2026

Why CVS Stock Rallied Tuesday Morning - The Motley Fool

<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxPdU1fMHVrLVcwUU05SDMySUphcG0tNndDb3FfR0NjUWNEdkxHM2VvZDNpR0hHNGttOHRHWjJ2NTY3ME5VYzJTVUZlS3JNa3dFWEJ6eTBJRTU1MXJoNkJtZDNUMExrd2pZZ3kxYzFNenE4WHVRYktEN3BYMG1yalRBZF9qTUVCSlE?oc=5" …

CVS — Frequently Asked Questions

What is the current share price of CVS Health Corporation (CVS)?

As of 2026-09-07 16:24 PDT, CVS Health Corporation (CVS) trades at $96.74 on NYSE. Its 52-week range is $63.87 to $109.92.

What is the market capitalisation of CVS?

CVS Health Corporation (CVS) has a market capitalisation of $123.73B on NYSE.

What is the P/E ratio of CVS?

CVS trades at a trailing price-to-earnings (P/E) ratio of 25.53. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 1.53.

Does CVS pay a dividend?

CVS Health Corporation (CVS) currently offers a dividend yield of 2.76%.

What is the return on equity (ROE) of CVS?

CVS has a return on equity (ROE) of 6.21%. Its return on capital employed (ROCE) is 6.30%.

Is CVS a good stock to buy?

This page provides a data-driven analysis of CVS Health Corporation (CVS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space